Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
基本信息
- 批准号:10260891
- 负责人:
- 金额:$ 112.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-14 至 2023-03-31
- 项目状态:已结题
- 来源:
- 关键词:AdherenceAntibodiesArchitectureAutoantibodiesAutoimmunityAwardBig DataBiologicalBiological MarkersCOVID-19Celiac DiseaseCharacteristicsClinical InvestigatorCollaborationsCommunicationConfidentiality of Patient InformationDataData AnalysesData CollectionData Coordinating CenterData Management ResourcesData SecurityData SetDevelopmentDiabetes MellitusDietDietary FactorsDiseaseDocumentationEducational workshopEnrollmentEnsureEvaluationFloridaFundingGene ExpressionGoalsHLA AntigensHealthImmune systemImmunologic MarkersIndividualInfectious AgentInfectious Diseases ResearchInformaticsInsulin-Dependent Diabetes MellitusLaboratoriesLiteratureLogisticsMaintenanceManualsMeasurementMessenger RNAMonitorNational Institute of Diabetes and Digestive and Kidney DiseasesPaperParticipantPathogenesisPerformancePeriodicityPlayPreparationProceduresProtocols documentationPsychosocial FactorPublicationsQuality ControlReportingResearchResearch PersonnelRoleSamplingSampling StudiesScheduleSecureServicesSite VisitSourceSpecific qualifier valueSpecimenStatistical Data InterpretationStudy SubjectTimeTimeLineTrainingUniversitiesViralViral AntibodiesViral MarkersVisitWorkclinical centerdata de-identificationdata qualitydata sharingdata warehousediabetes riskendocrine pancreas developmentenvironmental agentfollow up assessmentfollow-upmeetingsmetabolomicsmicrobiomeoperationpandemic diseasepreventprimary endpointrepositorysymposiumweb site
项目摘要
The University of South Florida is uniquely qualified to conduct the activities specified in this limited competition
RFA. The purpose of the RFA is to fund the continuation of the Data Coordinating Center’s (DCC's) functions
in support of TEDDY subject follow-up and to add funds for studies of viral markers (antibodies), including
COVID-19 and the integrative analysis of omics data. Competition will be sufficient to attract applications
from collaborators with the capability to perform reliable measurements of viral markers, and to make
the data available to TEDDY investigators for collaborative, integrative analyses. The proposed Data
Coordinating Center activities include: 1) Executing the study protocol for follow-up of TEDDY study
participants according to schedules and procedures contained in the study's Manual of Operations and in
collaboration with the Clinical Centers at which participants are enrolled and with NIDDK staff. 2) Receiving,
managing, and analyzing data obtained from the clinical centers 3). Monitoring of adherence to the research
plan by conducting site visits to monitor the quality of record keeping, source documentation and the accuracy
of data entry and also for overseeing data quality control. Steering Committee, subcommittee, and external
evaluation committee meetings and workshops.4). Providing statistical support, expertise and oversight
throughout the study. 5) Providing study-wide communications, dissemination of study materials such as
protocols, Manual of Operations, forms or other study documents, and development and maintenance of the
web site. 6) Playing a key role in the operational conduct of TEDDY, providing training and technical
assistance to the Clinical Centers in performance of the follow-up assessments; assisting in protocol
implementation; and working in conjunction with the Clinical Centers and NIDDK staff to oversee all aspects of
Clinical Center performance, including timeliness and quality of data and biosample submission. 7)
Procurement and administration of subcontracts for laboratory services, including: central human leukocyte
antigen laboratory; the autoantibody laboratories, the mRNA laboratories, infectious disease laboratories, and
other laboratories as needed. 8) Providing administrative and logistical support services for the TEDDY Study
Group including preparation of publications, and organizing periodic meetings for the study group and
subcommittees, workshops, and conference calls. 9) Transfer of all biosamples and data to the NIDDK central
repositories according to a timeline developed with the NIDDK. and 10) Working closely with the Clinical
Centers in a collaborative and interactive manner and serving on the Steering Committee. The solicitation of
external collaborators for studies of viral markers and integrative analyses will follow established mechanisms
for soliciting and evaluating proposals. The DCC has successfully done this for several core TEDDY labs and
this would be the third solicitation for integrative data analysis.
南佛罗里达大学是唯一有资格进行在这个有限的竞争指定的活动
射频消融RFA的目的是为数据协调中心(DCC)继续履行职能提供资金
支持TEDDY受试者随访,并为病毒标志物(抗体)的研究增加资金,包括
COVID-19和组学数据的综合分析。竞争将足以吸引申请
从合作者的能力进行可靠的测量病毒标志物,并使
TEDDY研究者可以利用这些数据进行协作和综合分析。所提出的数据
协调中心的活动包括:1)执行TEDDY研究随访的研究方案
根据研究操作手册中的时间表和程序,
与参与者入组的临床中心和NIDDK工作人员合作。2)接收,
管理和分析从临床中心获得的数据3)。监测研究依从性
通过进行现场访问来监控记录保存的质量、源文件和
数据输入和监督数据质量控制。指导委员会、小组委员会和外部
评估委员会会议和研讨会。4)。提供统计支助、专门知识和监督
在整个研究过程中。5)提供研究范围内的沟通,传播研究材料,如
方案、操作手册、表格或其他研究文件,以及
网站. 6)在TEDDY的运作中发挥关键作用,提供培训和技术
协助临床中心进行随访评估;协助方案
实施;并与临床中心和NIDDK工作人员合作,监督
临床中心绩效,包括数据和生物样本提交的及时性和质量。第七章)
实验室服务分包合同的采购和管理,包括:
抗原实验室;自身抗体实验室,mRNA实验室,传染病实验室,和
其他实验室如有需要。8)为TEDDY研究提供行政及后勤支援服务
包括编写出版物,为研究组组织定期会议,
小组委员会、研讨会和电话会议。9)将所有生物样本和数据转移至NIDDK中心
根据NIDDK制定的时间轴,(10)与临床
以协作和互动的方式与各中心合作,并在指导委员会中任职。征求
病毒标志物研究和综合分析的外部合作者将遵循既定机制
征求和评估建议。DCC已经成功地为几个核心TEDDY实验室做到了这一点,
这将是第三次请求进行综合数据分析。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFFREY P KRISCHER其他文献
JEFFREY P KRISCHER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFFREY P KRISCHER', 18)}}的其他基金
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
- 批准号:
10398923 - 财政年份:2021
- 资助金额:
$ 112.48万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10403442 - 财政年份:2021
- 资助金额:
$ 112.48万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10179934 - 财政年份:2021
- 资助金额:
$ 112.48万 - 项目类别:
Limited Competition: Continued Follow-up of Subjects and Initiation of a Second Case-control Cohort in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
有限的竞争:在年轻研究中糖尿病的环境决定因素(TEDDY)中继续对受试者进行随访并启动第二个病例对照队列
- 批准号:
10227415 - 财政年份:2021
- 资助金额:
$ 112.48万 - 项目类别:
Human gene transfer & macrophage cell transplantation therapy of hereditary PAP (hPAP)
人类基因转移
- 批准号:
10702185 - 财政年份:2021
- 资助金额:
$ 112.48万 - 项目类别:
Follow-up on Subjects, Integrative Data Analysis and Measurement of Viral Antibodies in The Environmental Determinants of Diabetes in The Young Study (TEDDY)
青年糖尿病环境决定因素研究(TEDDY)中的受试者跟踪、综合数据分析和病毒抗体测量
- 批准号:
10392400 - 财政年份:2020
- 资助金额:
$ 112.48万 - 项目类别:
NIDDK Follow-up on Subjects and Immunological Assessments in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4)
NIDDK 青年糖尿病环境决定因素研究 (TEDDY) (UC4) 中受试者和免疫学评估的后续行动
- 批准号:
10088137 - 财政年份:2017
- 资助金额:
$ 112.48万 - 项目类别:
Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3
1 型糖尿病数据协调中心 TrialNet (UC4)USF:TrialNet UC4-3
- 批准号:
9506924 - 财政年份:2017
- 资助金额:
$ 112.48万 - 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
- 批准号:
10249943 - 财政年份:2016
- 资助金额:
$ 112.48万 - 项目类别:
Multicenter Interventional Lymphangioleiomyomatosis Early Disease Trial (MILED) - DCC
多中心介入性淋巴管平滑肌瘤病早期疾病试验 (MILED) - DCC
- 批准号:
9743827 - 财政年份:2016
- 资助金额:
$ 112.48万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 112.48万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 112.48万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 112.48万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 112.48万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 112.48万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 112.48万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 112.48万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 112.48万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 112.48万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 112.48万 - 项目类别: